Voyager Therapeutics announced positive good laboratory practice (GLP) toxicology data for VY1706, its investigational tau silencing gene therapy for Alzheimer's disease. The data, presented at the Alzheimer’s Association International Conference, showed a favorable tolerability profile and significant target engagement in non-human primates, supporting the planned initiation of a clinical trial.
Key Details
- Favorable Safety Profile: In a six-month GLP toxicology study in non-human primates (NHPs), VY1706 demonstrated a favorable tolerability profile with no adverse findings in the central nervous system or peripheral organs up to the highest dose tested.
- Significant Target Engagement: A single intravenous dose achieved broad CNS delivery with up to 75% lowering of tau protein and MAPT mRNA in key brain regions relevant to Alzheimer's disease.
- Clinical Pathway: The company received FDA Investigational New Drug (IND) clearance for VY1706 in June 2026 and plans to initiate a dose-escalation clinical trial in the second half of 2026.